NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyGlobeNewsWire • 04/09/24
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/20/24
NuCana Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/16/23
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023GlobeNewsWire • 10/16/23
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023GlobeNewsWire • 10/13/23
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' NowZacks Investment Research • 09/28/23
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023GlobeNewsWire • 09/18/23
NuCana Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/16/23
NuCana Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/17/23
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of ActionGlobeNewsWire • 04/14/23
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 04/04/23
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not ValidGlobeNewsWire • 03/24/23